| pubmed-article:7543029 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7543029 | lifeskim:mentions | umls-concept:C0024299 | lld:lifeskim |
| pubmed-article:7543029 | lifeskim:mentions | umls-concept:C0001554 | lld:lifeskim |
| pubmed-article:7543029 | lifeskim:mentions | umls-concept:C0442027 | lld:lifeskim |
| pubmed-article:7543029 | lifeskim:mentions | umls-concept:C0015133 | lld:lifeskim |
| pubmed-article:7543029 | lifeskim:mentions | umls-concept:C1514463 | lld:lifeskim |
| pubmed-article:7543029 | lifeskim:mentions | umls-concept:C0348016 | lld:lifeskim |
| pubmed-article:7543029 | lifeskim:mentions | umls-concept:C0442967 | lld:lifeskim |
| pubmed-article:7543029 | lifeskim:mentions | umls-concept:C0439590 | lld:lifeskim |
| pubmed-article:7543029 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:7543029 | lifeskim:mentions | umls-concept:C0332173 | lld:lifeskim |
| pubmed-article:7543029 | lifeskim:mentions | umls-concept:C0085752 | lld:lifeskim |
| pubmed-article:7543029 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:7543029 | pubmed:dateCreated | 1995-9-5 | lld:pubmed |
| pubmed-article:7543029 | pubmed:abstractText | Prolonged daily administration of oral etoposide has been reported to be active in refractory lymphoma. The purpose of this phase II trial was to confirm the activity of this schedule of etoposide in a selected group of heavily pretreated patients with non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD). A total of 26 patients (20 with NHL and 6 with HD) were entered in the trial; all had previously been treated with an Adriamycin-based chemotherapy, an ifosfamide-containing salvage combination, and i.v. etoposide. Etoposide was given in a fixed oral daily dose of 100 mg over 3 weeks; the weekly dose (500-700 mg) was selected such that the average daily dose was approximately 50 mg/m2. Cycles were repeated on day 29. An objective response was seen in 16 patients (62%; 95% confidence interval, 42%-80%), with a complete response (CR) being observed in 3 cases (12%) and a partial response (PR), in 13 (50%). The median duration of PRs was 3 months. CRs lasted for 15 months in one patient and continue at 12+ and 20+ months in the remaining two patients. The overall actuarial survival for the entire group was 40% at 2 years; the median survival time was 12 months. The main toxicity was myelosuppression; WHO grade 3 or 4 leukopenia and thrombocytopenia developed in 31% and 12% of the patients, respectively. There was no drug-related death. We conclude that oral etoposide is an effective and tolerable palliative treatment for heavily pretreated lymphoma patients. | lld:pubmed |
| pubmed-article:7543029 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7543029 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7543029 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7543029 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7543029 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7543029 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7543029 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7543029 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7543029 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7543029 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7543029 | pubmed:issn | 0344-5704 | lld:pubmed |
| pubmed-article:7543029 | pubmed:author | pubmed-author:HaimNN | lld:pubmed |
| pubmed-article:7543029 | pubmed:author | pubmed-author:Ben-ShaharMM | lld:pubmed |
| pubmed-article:7543029 | pubmed:author | pubmed-author:EpelbaumRR | lld:pubmed |
| pubmed-article:7543029 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7543029 | pubmed:volume | 36 | lld:pubmed |
| pubmed-article:7543029 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7543029 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7543029 | pubmed:pagination | 352-5 | lld:pubmed |
| pubmed-article:7543029 | pubmed:dateRevised | 2006-4-24 | lld:pubmed |
| pubmed-article:7543029 | pubmed:meshHeading | pubmed-meshheading:7543029-... | lld:pubmed |
| pubmed-article:7543029 | pubmed:meshHeading | pubmed-meshheading:7543029-... | lld:pubmed |
| pubmed-article:7543029 | pubmed:meshHeading | pubmed-meshheading:7543029-... | lld:pubmed |
| pubmed-article:7543029 | pubmed:meshHeading | pubmed-meshheading:7543029-... | lld:pubmed |
| pubmed-article:7543029 | pubmed:meshHeading | pubmed-meshheading:7543029-... | lld:pubmed |
| pubmed-article:7543029 | pubmed:meshHeading | pubmed-meshheading:7543029-... | lld:pubmed |
| pubmed-article:7543029 | pubmed:meshHeading | pubmed-meshheading:7543029-... | lld:pubmed |
| pubmed-article:7543029 | pubmed:meshHeading | pubmed-meshheading:7543029-... | lld:pubmed |
| pubmed-article:7543029 | pubmed:meshHeading | pubmed-meshheading:7543029-... | lld:pubmed |
| pubmed-article:7543029 | pubmed:meshHeading | pubmed-meshheading:7543029-... | lld:pubmed |
| pubmed-article:7543029 | pubmed:meshHeading | pubmed-meshheading:7543029-... | lld:pubmed |
| pubmed-article:7543029 | pubmed:meshHeading | pubmed-meshheading:7543029-... | lld:pubmed |
| pubmed-article:7543029 | pubmed:meshHeading | pubmed-meshheading:7543029-... | lld:pubmed |
| pubmed-article:7543029 | pubmed:meshHeading | pubmed-meshheading:7543029-... | lld:pubmed |
| pubmed-article:7543029 | pubmed:meshHeading | pubmed-meshheading:7543029-... | lld:pubmed |
| pubmed-article:7543029 | pubmed:meshHeading | pubmed-meshheading:7543029-... | lld:pubmed |
| pubmed-article:7543029 | pubmed:meshHeading | pubmed-meshheading:7543029-... | lld:pubmed |
| pubmed-article:7543029 | pubmed:meshHeading | pubmed-meshheading:7543029-... | lld:pubmed |
| pubmed-article:7543029 | pubmed:meshHeading | pubmed-meshheading:7543029-... | lld:pubmed |
| pubmed-article:7543029 | pubmed:meshHeading | pubmed-meshheading:7543029-... | lld:pubmed |
| pubmed-article:7543029 | pubmed:meshHeading | pubmed-meshheading:7543029-... | lld:pubmed |
| pubmed-article:7543029 | pubmed:meshHeading | pubmed-meshheading:7543029-... | lld:pubmed |
| pubmed-article:7543029 | pubmed:meshHeading | pubmed-meshheading:7543029-... | lld:pubmed |
| pubmed-article:7543029 | pubmed:meshHeading | pubmed-meshheading:7543029-... | lld:pubmed |
| pubmed-article:7543029 | pubmed:meshHeading | pubmed-meshheading:7543029-... | lld:pubmed |
| pubmed-article:7543029 | pubmed:meshHeading | pubmed-meshheading:7543029-... | lld:pubmed |
| pubmed-article:7543029 | pubmed:year | 1995 | lld:pubmed |
| pubmed-article:7543029 | pubmed:articleTitle | Prolonged daily administration of oral etoposide in lymphoma following prior therapy with adriamycin, an ifosfamide-containing salvage combination, and intravenous etoposide. | lld:pubmed |
| pubmed-article:7543029 | pubmed:affiliation | Department of Oncology, Rambam Medical Center, Haifa, Israel. | lld:pubmed |
| pubmed-article:7543029 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7543029 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:7543029 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7543029 | lld:pubmed |
